New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

ESBRIET ® (pirfenidone) capsules and film-coated tablets, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

ESBRIET is a prescription medicine for lung disease called idiopathic pulmonary fibrosis (IPF) treatment.
INDICATIONS AND USAGE
ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DOSAGE FORMS & STRENGTHS
• Capsules: 267 mg
• Tablets: 267 mg, 801 mg
Manufactured By: Genentech
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “ESBRIET ® (pirfenidone) capsules and film-coated tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.

It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014. There is also a topical form created for the treatment of abnormal wound healing processes.

Related Products